NCT01395147 - Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Major Depressive Disorder

Interventions

DRUG

Lu AA21004

Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.

Trial Locations (32)

Unknown

Inzai-shi

Noda

Fukuoka

Kitakyushu-shi

Annaka-shi

Fujioka-shi

Takasaki-shi

Hatsukaichi-shi

Hiroshima

Sapporo

Amagasaki-shi

Kobe

Ibaraki

Fujisawa-shi

Kawasaki-shi

Sagamihara-shi

Yokohama

Osaka

Kumamoto

Kyoto

Kurashiki-shi

Osaka

Fukaya-shi

Saitama

Utsunomiya

Anan-shi

Tokushisma-shi

Hachioji-shi

Katsushika-ku

Musashino-shi

Tokyo

Nanyo-shi